22 results about "Metabolic change" patented technology

The application discloses a method for screening garlic fructan adversity response key enzyme genes and metabolites based on transcriptome and metabolome, and the method can better analyze the relationship between genes and metabolites by jointly analyzing the fructan-related differentially expressed genes measured by the transcriptome and the fructan-related metabolism substances with obvious metabolism changes measured by the metabolome, and constructing a gene-metabolite network interaction diagram.

The invention discloses application of a fucoidin degradation product Fuc-S in a pharmaceutical composition for preventing, relieving or treating type 2 diabetes mellitus and liver injury, and relates to the technical field of biological medicines. The invention provides a new effect of fucoidin Fuc-S in treating diabetic liver injury, and particularly, the fucoidin Fuc-S can significantly improve blood glucose control (reducing fasting blood glucose and enhancing sugar tolerance) and blood lipid spectrum (reducing TG, TC and LDL-C and increasing HDL-C) of diabetic mice, alleviate liver fatty degeneration and reduce serum ALT / AST level, and shows a significant liver protection effect. Furthermore, the Fuc-S can be used for remodeling the intestinal flora structure through specific enrichment of beneficial bacteria such as Bacteroides acdifaciens and the like, so that the generation of short-chain fatty acid (SCFAs) with a liver protection effect is promoted. The flora and metabolic change jointly improve the oxidative stress state of the liver, inhibit pro-inflammatory response and reduce lipid accumulation. The invention provides a novel nutrition intervention strategy for prevention and treatment of T2DM and liver complications thereof.

This invention relates to the field of multi-organ dysfunction (MOD) early warning technology, specifically to an MOD early warning method for patients with severe burns. The method includes the following steps: acquiring heart rate, mean arterial pressure, respiratory rate, blood oxygen saturation, lactate concentration, and urine output per unit time; calculating the rate of lactate change at adjacent time points to form a sequence; comparing the rate of change across time intervals to obtain the difference in change; combining heart rate and blood oxygen saturation to calculate circulatory load; and counting the number of early warning triggers that meet risk conditions. In this invention, by calculating the rate of change of lactate concentration at adjacent time points and combining it with interval direction statistics, tissue metabolic changes show trend characteristics; the rate of change of urine output combined with mean arterial pressure forms a record of renal perfusion changes, providing a continuous characterization of perfusion status; heart rate and blood oxygen saturation are used to calculate circulatory load; multiple physiological signals are linked for judgment; and recurring abnormalities are expressed through the number of triggers. This improves the stability and predictability of MOD risk identification in critically burned patients.

The application relates to application of phosphatidylinositol and phosphatidylglycerol as metabolic markers for predicting intracranial atherosclerosis progression, and belongs to the technical field of medical biological detection. In the scheme, single-sample MR analysis is carried out by combining RICAS cohort data with external database data, causal correlation between metabolites and ICAS is analyzed, and serum biomarkers phosphatidylinositol PI 18:0 / 22:6 and phosphatidylglycerol PG 18:1 / 18:2 for ICAS occurrence and development are screened out by combining characteristic metabolic changes of ICAS with causal correlation analysis. ICAS progression is collected through prospective follow-up of the RICAS cohort, the correlation between the serum biomarkers and the ICAS progression is established, and it is verified that the serum biomarkers have transformation application value and can be used as a new biomarker for early prediction of ICAS progression and derivation.

The invention discloses application of glucoraphanin to preparation of a product for reducing biological accumulation of perfluorooctane sulfonate, and belongs to the technical field of biological medicine. The occurrence probability of the high PFOS level in the body of a participant frequently eating broccoli is confirmed to be remarkably reduced through population epidemiological experiments, and then the PFOS level in the body of the participant is confirmed to be remarkably reduced after glucoraphanin intervention through clinical RCT random control experiments. The glucoraphanin-intervened serum has the advantages that the glucoraphanin-intervened serum is used as a main body, the metabolic change of steroid, ceramide and bile acid in the glucoraphanin-intervened serum is confirmed to be closely related to the reduction of the PFOS level through lipidomics analysis, and finally, the glucoraphanin is confirmed to be capable of effectively reducing the PFOS in-vivo accumulation and improving the liver injury caused by the PFOS through animal experiments and an AI reverse targeting technology; and the glucoraphanin and the in-vivo metabolite sulforaphane thereof have relatively strong binding capacity with a liver-specific PXR receptor, so that a good technical foundation is laid for research and development of drugs for treating diseases related to PFOS accumulation.

According to the compound anti-tumor screening method provided by the invention, a cell metabolism phenotype model, namely a D-lactic acid cell model, is established, and a compound capable of reducing abnormal change of metabolite content induced by D-lactic acid is screened by taking a cell metabolism profile as a detection index. According to the method, a progressive evaluation system from in-vitro metabonomics screening to in-vivo pharmacodynamic verification is adopted, compounds influencing the change of the metabolite content of cells are effectively recognized and evaluated, the limitation of traditional tumor drug screening is broken through, the cell metabolism change caused by D-lactic acid is focused, the targeting property and reliability of anti-cancer drug development are remarkably improved, and the method is suitable for clinical application. And an innovative technical path is provided for treating tumors related to abnormal metabolism.

The invention relates to the field of medical health, in particular to a breast cancer liver metastasis risk dynamic monitoring and early warning system based on metabonomics, which comprises a data acquisition and preprocessing module for acquiring venous blood samples at three time points of disease progression of a patient, measuring specific metabolite concentration and performing normalization processing; the dynamic feature extraction module calculates a gain index, namely the sum of the change rates of the indexes; the deep learning modeling module uses the first and second deep networks to train sample data in different time periods, and establishes a patient disease prediction model. The comprehensive evaluation module adopts an ROC curve and an AUC value to evaluate the prediction accuracy of the model; the risk early warning module generates a liver metastasis risk early warning signal according to the evaluation result; according to the system, the breast cancer liver metastasis risk is dynamically monitored through metabonomics data acquisition and analysis at multiple time points, the metabolic change trend in disease progression is reflected more accurately, and early warning of the liver metastasis risk is achieved.

The invention relates to a method for noninvasively evaluating age-dependent metabolic characteristics of mouse oocytes. The method comprises the following steps: S1, collecting oocytes of mice at different month ages; s2, treating the oocytes to obtain a sample capable of being used for spontaneous Raman spectroscopy and imaging; s3, performing spontaneous Raman spectroscopy and imaging of different oocytes; s4, processing and analyzing Raman spectrum data; s5, processing and analyzing two-dimensional and three-dimensional Raman imaging; s6, analyzing morphological and spectral characteristics of oocytes of mice of different age groups; and S7: determining the specific age-related change of the lipid content and distribution, the cytochrome c level and the metabolic profile in the mouse oocytes. Compared with the prior art, the method has the advantages that the metabolic change of the oocytes of mice with different maternal ages is analyzed by Raman spectrum for the first time, the age-dependent distribution change of lipid and cytochrome c is revealed through high-resolution subcellular mapping, and a new research scheme is provided for the biochemical mechanism of oocyte senescence.

A method for treating low-level blast traumatic brain injury includes administering a phosphodiesterase-5 (PDE5) inhibitor, such as sildenafil, to a subject following exposure of the subject to one or more low-level blasts. Administration of the PDE5 inhibitor may prove useful with respect to improving the vascular integrity of a subject by increasing brain capillary respiration, mitochondrial respiration, mitochondrial density, mitochondrial biogenesis, astrocyte level or homeostasis, and / or tight junction protein expression in the brain of the subject and / or inducing positive metabolic change in the subject by increasing NAD+ / NADH metabolism. Methods for mitigating the effects of blast injury on the vascular integrity of a subject and inducing metabolic change are also provided.

The application belongs to the technical field of biological analysis and detection, and discloses a method for extracting, measuring and mass spectrum imaging visualizing high-order characteristic information of spatial metabolome. Specifically, the application relates to a mass spectrum imaging analysis method for evaluating the in-vivo active action site and action intensity of a preclinical candidate drug, which can be applied to the prediction of potential action sites, molecular targets and molecular mechanisms of a drug. The index "metabolic disturbance score" introduced in the application can be used to measure the change of high-order characteristics of spatial metabolome, and the metabolic changes of different spatial sites can be visually represented in images, so that the overall metabolic state change of each part of the body under the action of the candidate drug can be objectively evaluated. In addition, the application can be used to evaluate the influence of the drug on specific metabolic pathways, species, functions or biological transformation types, which is helpful to explain the potential molecular mechanism of the drug action and accelerate the discovery of new drug targets and clinical indications in the pharmaceutical industry.

The invention relates to application of phosphatidylinositol and phosphatidylglycerol as metabolic markers for predicting the progress of intracranial atherosclerosis, and belongs to the technical field of medical biological detection. According to the scheme, RICAS queue data and external database data are combined for single-sample MR analysis, the causal association between metabolites and ICAS is analyzed, ICAS characteristic metabolic change and causal association analysis are combined, serum biomarkers of phosphatidylinositol PI 18: 0 / 22: 6 and phosphatidylglycerol PG 18: 1 / 18: 2 of ICAS occurrence and development are screened out, ICAS progress is collected through prospective follow-up visit of an RICAS queue, and the ICAS development rate is improved. The association between the gene and ICAS progress is established, and the gene has a transformation application value and can be used as a novel biomarker for early prediction of ICAS progress and development.

According to the method for detecting the early pregnancy of the cattle by using the metabonomics technology, tiny metabolic changes in bovine serum can be detected through the metabonomics technology, the pregnancy state can be accurately judged even in the early pregnancy stage, and the detection sensitivity is improved. The differential metabolites screened out through multivariate statistical analysis and a machine learning algorithm have high specificity, pregnant cattle and non-pregnant cattle can be effectively distinguished, and misdiagnosis and missed diagnosis are reduced. The sample collection and pretreatment processes are relatively simple, complex equipment and professional skills are not needed, and the method is suitable for rapid detection of large-scale farms. Detection can be carried out 18-25 days after cattle hybridization, the pregnancy state can be judged earlier than that of a traditional method, and more timely information is provided for breeding management of cattle herds.

The invention discloses application of a microbiota-metabolite combined marker in screening gastric cancer biomarkers, and belongs to the technical field of biology. According to the application of the microbiota-metabolite combined marker in screening of gastric cancer biomarkers, GM and metabonomics data are integrated, and microbe and metabolic changes in specific stages along the CS are described. Atrophy represents a key inflection point of transition from in vivo equilibrium to carcinogenesis, and erosion is a transition state. The microbiota-metabolite combined marker is expected to be used for mechanism insight of non-invasive early detection, disease stratification and GC metabolism dependence.

The invention relates to the technical field of biomedicine and nutriology, and relates to a composition for targeted inhibition of lipid peroxidation to promote plateau study and application. Specifically, protein change characteristics of plateau hypoxia stress cells or mouse tissues are analyzed through a proteome technology, a lipid metabolism change rule in the plateau hypoxia stress mouse tissues is analyzed through a targeted lipid metabolome technology, and lipid peroxidation damage of hypoxia to the cells is analyzed through tests such as MDA content determination, ATP content determination and CCK8 cell activity detection. And providing a scheme of jointly supplementing iron and oleic acid to promote plateau exercise, and verifying in animal experiments. The iron and the olive oil are supplemented into the feed at the same time, so that the oxygen partial pressure and the oxyhemoglobin saturation of the mouse can be further improved while the mouse resists lipid peroxidation damage caused by high altitude hypoxia. The combined supplement of iron and olive oil can reduce tissue damage and improve the plateau taking ability of the organism, and the method is a safe and effective plateau taking promoting strategy.

The present application relates to physiological spectrum data processing technical field, specifically to a kind of cerebral oxygen metabolism detection method and system based on near infrared spectrum.The method determines the main component in light attenuation signal, obtains low-frequency blood oxygen regulation component reflecting user physiological activity or metabolic change after being eliminated.Based on the characteristics between low-frequency blood oxygen regulation component and main signal component, pulse conduction blood oxygen component is obtained using modified Lambert-Beer law.Based on low-frequency blood oxygen regulation component and pulse conduction blood oxygen component, the asymmetry between left and right brain can be analyzed, risk comprehensive index is determined using signal difference between the two components, and then metabolic early warning signal is effectively fed back.The present application obtains the characteristic signal of cerebral blood vessel in blood flow regulation and pulse conduction by effective signal decomposition method, avoids the interference of other factors on information, and obtains accurate early warning result.

Autophagy is typically activated by starvation, allowing cells and organisms to mobilize their energy reserves. It is known that pharmacological modulation of autophagy represents a therapeutic potential. Here the inventors report that a protein that is released from cells in an unconventional, autophagy-dependent manner, namely, diazepam binding inhibitor (DBI), regulates autophagy. In particular, the inventors demonstrate that DBI inhibits autophagy and that the supply of recombinant DBI to mice enhanced glycolysis, enhanced lipogenesis, and inhibited fatty acid oxidation. The inventors show that neutralisation of DBI by a monoclonal antibody and an active immunization by means of an immunogenic DBI derivative eliciting autoantibodies induce autophagy and lead to metabolic changes that increase starvation-induced weight loss, reduce food intake upon refeeding, and reduce weight gain in response to hypercaloric diets. Accordingly, the present invention relates to methods and pharmaceutical compositions for modulating autophagy based on the modulation of the activity or expression of DBI.

The invention relates to the technical field of medication management, and discloses a tumor patient medication safety intelligent management system, which comprises a data acquisition and integration module, an intelligent analysis and decision module, a medication process management module, a monitoring and feedback module and an optimization module, by constructing an integrated framework of'multi-source data fusion-intelligent analysis and decision-dynamic accurate management ', clinical data of patients, drug attribute data and dynamic drug interaction data are fused, and a machine learning algorithm is applied to establish a personalized drug metabolism kinetic model; the method realizes the crossing from universal medication management to personalized and dynamic management, can accurately predict the metabolic change of the drug in the body of the patient, dynamically evaluates the drug interaction risk in combination with the real-time physiological state, avoids the potential medication safety problem in advance, standardizes the whole medication process through the knowledge graph, reduces the manual operation error, and improves the medication safety. And the accuracy and normalization of medication safety management of tumor patients are greatly improved.

The invention discloses a construction method of an obesity and sepsis combined rat model, and belongs to the technical field of medicine. In order to solve the problem that a targeted obesity-combined sepsis animal model is lacked in the prior art, the invention provides a construction method of an obesity-combined sepsis rat model, through collaborative design of obesity basis and sepsis strike, rats are induced by standard sepsis under the obesity metabolism background, and the obesity-combined sepsis animal model is obtained. Therefore, key pathological characteristics of clinical obesity and sepsis combined patients can be reproduced; the model obtained through the construction method can be used for researching pathogenesis, immune metabolism change and treatment response of sepsis in the obesity state, and new experimental tools and thoughts are provided for optimizing clinical treatment of special crowds.

The invention belongs to the technical field of traditional Chinese medicine quality control and analysis, and particularly discloses a method for screening paris polyphylla quality markers. According to the method, a blood stasis syndrome animal model is constructed, a biological sample of the blood stasis syndrome animal model is collected, an endogenous biomarker set is generated in combination with metabonomics analysis, meanwhile, quantitative analysis is conducted on the callback degree after drug intervention, and the relevance between pharmacodynamic substances and metabolic changes is revealed. In-vitro chemical analysis is carried out on paris polyphylla related materials to obtain chemical component spectrum data, and blood entering component data is extracted in combination with serum drug chemical analysis, so that accurate positioning of potential drug effect substances is realized. Finally, the paris polyphylla quality marker is screened out through traceability comparison and a comprehensive evaluation system, and a scientific basis is provided for quality control of traditional Chinese medicine. The accuracy of the screening result is improved, the repeatability and reliability of the screening process are guaranteed, and the misjudgment risk caused by data deviation is reduced.

The invention provides an sTBI prognosis prediction method and device and electronic equipment, and relates to the technical field of crossing of medical information technologies and clinical neurosciences. Biomarker data, multi-omics data and corresponding brain imaging data of multiple periods from an acute period to a recovery period after brain injury of a patient are obtained; and the dynamic change of molecules and images in the pathological process is comprehensively captured. Multiple omics expression trends are associated through biomarkers, brain injury prognosis core key molecules are accurately positioned, and false positive interference of a traditional method is avoided. The change of the anatomical structure of the brain injury is combined with the change of functional metabolism, so that the pathophysiological state of the brain injury is comprehensively reflected. On the premise, time sequence correlation is carried out on the multi-dimensional data, and a new strategy is provided for improving the sTBI clinical curative effect by revealing the dynamic evolution rule of the brain injury data and constructing a precise intervention system.

The invention relates to the technical field of physiological spectrum data processing, in particular to a brain oxygen metabolism detection method and system based on a near infrared spectrum. According to the method, main components in light attenuation signals are determined, and low-frequency blood oxygen regulation components reflecting physiological activities or metabolic changes of a user are obtained after the main components are removed. Based on the characteristics between the low-frequency blood oxygen adjusting component and the main signal component, the pulse conduction blood oxygen component is obtained through the modified Lambert-Beer law. The asymmetry between the left brain and the right brain can be analyzed based on the low-frequency blood oxygen adjustment component and the pulse conduction blood oxygen component, the risk comprehensive index is determined through the signal difference between the two components, and then metabolism early warning signals are effectively fed back. According to the invention, through an effective signal decomposition mode, characteristic signals of cerebral vessels in two aspects of blood flow regulation and pulse conduction are obtained, interference of other factors on information is avoided, and an accurate early warning result is obtained.

The invention relates to the field of dairy products, and discloses a novel dairy product and a preparation method thereof. According to the invention, fermented milk rich in probiotics is selected to intervene mice with allergic rhinitis, and results show that the rhinitis symptom of the mice is significantly reduced through intervention, and intestinal flora and metabolic changes are improved. The formula powder rich in nutrient elements is selected for intervention, and the result shows that the rhinitis symptom of the mouse is remarkably reduced through intervention, and intestinal flora and metabolic changes are improved. The effect of intervening the mouse with allergic rhinitis by mixing the formula powder and the fermented milk is more remarkable than that of intervening by singly adopting the formula powder or the fermented milk. The method has the effect of preventing and treating the allergic rhinitis, and a new thought is provided for the method for preventing and treating the allergic rhinitis.